Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study

Study limitation reported by the research below: “Tofacitinib subgroup (n=74) is notably smaller than ustekinumab (n=135) and upadacitinib (n=103), which may affect the stability of IPTW-weighted estimates for that arm.”